Paris, 18 March 2008 – Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialised in protein-protein interactions, announces its revenues for the year ended 31 December 2007......Significant progress in cancer-related R&D programmes :
-Inecalcitol: very good tolerance at the daily oral dose of 80 microgrammes
The clinical development of inecalcitol, a vitamin D analogue, is progressing swiftly. The tolerance Phase II trial started with the treatment of the first patient in November 2007, and now ongoing at six centres in France: the Georges Pompidou, Saint-Joseph and Beaujon Hospitals and Institut Curie in Paris, the Cancer Centre Lacassagne in Nice and the University Hospital in Besançon. Three cohorts of patients are currently being treated, and the highest dose is 80 microgrammes per day, taken orally, for 18 weeks. No signs of hypercalcemia, which is the major side-effect of natural vitamin D, have been observed to date.
-Ubiquitin-specific protease inhibitors: selection of HBX 99200
Hybrigenics' research programme focusing on new anti-cancer molecules has been validated by results obtained by the US National Cancer Institute. After in vitro tests on 60 cell lines and vivo research in mice, HBX 99,200 has been selected for evaluation in rats that will receive grafts of prostate cancer, breast cancer and melanoma cells. HBX 99,200 is an inhibitor ubiquitin-specific proteases, which is a new class of therapeutic targets for cancer treatment... [PDF] Hybrigenics' Press Release - PDF du Communiqué de Presse Hybrigenics -
